269.67
Iqvia Holdings Inc stock is traded at $269.67, with a volume of 1.44M.
It is up +1.51% in the last 24 hours and up +13.95% over the past month.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
See More
Previous Close:
$265.67
Open:
$263.17
24h Volume:
1.44M
Relative Volume:
1.01
Market Cap:
$44.39B
Revenue:
$16.63B
Net Income/Loss:
$1.39B
P/E Ratio:
33.43
EPS:
8.0674
Net Cash Flow:
$2.12B
1W Performance:
+4.04%
1M Performance:
+13.95%
6M Performance:
+63.71%
1Y Performance:
+45.01%
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IQV
Iqvia Holdings Inc
|
269.67 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
|
TMO
Thermo Fisher Scientific Inc
|
641.39 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
209.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
350.78 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
150.27 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Mar-06-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
IQVIA Holdings stock gains support as $2 billion notes offering underpins balance sheet - ad-hoc-news.de
IQVIA Holdings Announces $2 Billion Senior Notes Offering - The Globe and Mail
IQVIA (NYSE: IQV) Announces $2 Billion Senior Notes Offering to Refinance Existing Debt - Kalkine Media
IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector? - Yahoo Finance
IQVIA Holdings stock dips as USD 2 billion notes add to debt debate - ad-hoc-news.de
Form 8K IQVIA Holdings Inc For: 10 September By Investing.com - Investing.com Canada
IQVIA Holdings stock heads into the open after a 3.2 percent drop - ad-hoc-news.de
IQVIA Announces Pricing of Senior NotesSeptember 9, 2026 - biospace.com
IQVIA Holdings Inc. (IQV) Announces $2 Billion Senior Notes Offe - GuruFocus
IQVIA stock rises amid $2 billion senior notes offering By Investing.com - Investing.com South Africa
IQVIA Subsidiary Prices $2 Billion of 2034 Senior Notes - marketscreener.com
IQVIA prices $2.0B of 2034 senior notes at 6.375% to refinance 2026 debt - TradingView
IQVIA (NYSE: IQV) plans $2B notes sale to redeem 2026 bonds and reduce credit-line debt - Stock Titan
IQVIA Holdings Inc. Announces Pricing of $2,000,000,000 Senior Notes Due 2034 - marketscreener.com
IQVIA Announces Offering of Senior Notes - iqvia.com
IQVIA Holdings stock falls as new USD 2 billion notes offering tightens funding profile - ad-hoc-news.de
IQV Stock Quote Price and Forecast - CNN
Is IQVIA Holdings (NYSE:IQV) Ready for More Attention? - Kalkine Media
IQVIA Holdings Inc. (IQV) latest stock news and headlines - Yahoo Finance UK
IQVIA Holdings Inc (IQV) Stock Down 3.2% but Still Overvalued -- GF Score: 90/100 - GuruFocus
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IQVIA (IQV): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
IQVIA Holdings stock gains on earnings beat and higher guidance - AD HOC NEWS
IQVIA Holdings, Inc. (IQV) Stock Analysis: Strong Analyst Consensus with 3.18% Potential Upside - DirectorsTalk Interviews
IQVIA Holdings stock holds near its yearly high - ad-hoc-news.de
IQVIA (IQV) Insider James Berkshire Sells 2,668 Shares - GuruFocus
Iqvia EVP James Berkshire sells $697k in company stock By Investing.com - Investing.com Australia
IQVIA Holdings EVP James G. Berkshire Executes Stock Appreciation Rights and Sells Shares - kalkinemedia.com
Iqvia EVP James Berkshire sells $697k in company stock - Investing.com
IQVIA Holdings (NYSE: IQV) executive sells and transfers over 5,300 shares - stocktitan.net
IQVIA Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
IQVIA Holdings Inc. (IQV) Peer Comparison – Compare with Others - valueresearchonline.com
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster - marketscreener.com
IQV Looks 9.6% Overvalued on GF Value™ as AI-Driven Clinical Inn - GuruFocus
James G. Berkshire plans $697K IQVIA (NYSE: IQV) stock sale - stocktitan.net
HSBC Adjusts Price Target on IQVIA Holdings to $300 From $280, Maintains Buy Rating - marketscreener.com
IQVIA Holdings (IQV) Q1 2026 Earnings Call Transcript - Fortune
IQVIA Holdings (IQV) Stock Analysis: Navigating Growth In The Healthcare Sector - DirectorsTalk Interviews
How Strong Q2 Beat And Raised 2026 Guidance At IQVIA Holdings (IQV) Has Changed Its Investment Story - Yahoo Finance
IQVIA's AI tool cut diabetes screening work by 99.5% and won an award - Stock Titan
IQVIA Holdings (IQV) Rallies On AI And Data Narrative As Fair Value Stays In View - sahmcapital.com
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now - Eastern Progress
IQVIA Holdings, Inc. (IQV) Stock Analysis: A Look at Strong Buy Ratings and Revenue Growth in Healthcare - DirectorsTalk Interviews
IQVIA Holdings Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Iqvia Holdings stock hits 52-week high at $260.32 - Investing.com
Iqvia Holdings stock hits 52-week high at $260.32 By Investing.com - Investing.com India
IQVIA Holdings | 8-K: IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance - Moomoo
IQVIA Holdings Stock Outlook: Is Wall Street Bullish or Bearish? - inkl
9,249 Shares in IQVIA Holdings Inc. $IQV Purchased by Wealthfront Advisers LLC - MarketBeat
IQVIA Holdings stock trades close to 52 week high as recent earnings and outlook support elevated va - Ad-hoc-news.de
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):